Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

MoonLake Immunotherapeutics (MLTX) Notes Payables (2020 - 2022)

MoonLake Immunotherapeutics' Notes Payables history spans 3 years, with the latest figure at $150000.0 for Q1 2022.

  • Quarterly Notes Payables changed N/A to $150000.0 in Q1 2022 from the year-ago period, while the trailing twelve-month figure was $150000.0 through Mar 2022, changed N/A year-over-year, with the annual reading at $15.0 million for FY2021, 25734.01% up from the prior year.
  • Notes Payables came in at $150000.0 for Q1 2022, down from $15.0 million in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $15.0 million in Q4 2021 to a low of $58063.0 in Q4 2020.
  • The 3-year median for Notes Payables is $150000.0 (2022), against an average of $5.1 million.
  • The largest YoY upside for Notes Payables was 25734.01% in 2021 against a maximum downside of 25734.01% in 2021.
  • MoonLake Immunotherapeutics' Notes Payables stood at $58063.0 in 2020, then surged by 25734.01% to $15.0 million in 2021, then tumbled by 99.0% to $150000.0 in 2022.
  • Per Business Quant, the three most recent readings for MLTX's Notes Payables are $150000.0 (Q1 2022), $15.0 million (Q4 2021), and $58063.0 (Q4 2020).